ARTICLE | Clinical News

Sinogliatin: Phase Ic data

August 24, 2015 7:00 AM UTC

An open-label Phase Ic trial in 24 Type II diabetics showed that once- and twice-daily 75 mg HMS5552 reduced mean HbA1c by 1% at week 4 from a baseline HbA1c of 8.9%. HMS5552 is in Phase II testing. H...